FDA Pharmacogenomics Guide Needs Process To Accept Biomarkers – PhRMA

FDA should define a process to prospectively validate biomarkers for pharmacogenomic product approval, the Pharmaceutical Research & Manufacturers of America said in comments on an FDA draft guidance

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Pink Sheet